Avadel Pharmaceuticals plc (AVDL)
USD 8.52
(2.53%)
USD 8.52
(2.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 27.96 Million USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | -100.0% |
| 2020 | 22.33 Million USD | -62.28% |
| 2019 | 59.21 Million USD | -42.66% |
| 2018 | 103.26 Million USD | -40.22% |
| 2017 | 172.74 Million USD | 14.97% |
| 2016 | 150.24 Million USD | -13.26% |
| 2015 | 173.2 Million USD | 1072.31% |
| 2014 | 14.77 Million USD | -34.17% |
| 2013 | 22.44 Million USD | -14.01% |
| 2012 | 26.1 Million USD | -19.94% |
| 2011 | 32.6 Million USD | -12.12% |
| 2010 | 37.09 Million USD | -11.93% |
| 2009 | 42.11 Million USD | 9.06% |
| 2008 | 38.61 Million USD | 5.36% |
| 2007 | 36.65 Million USD | 59.23% |
| 2006 | 23.02 Million USD | -2.45% |
| 2005 | 23.59 Million USD | -57.41% |
| 2004 | 55.41 Million USD | 120.17% |
| 2003 | 25.16 Million USD | 36.73% |
| 2002 | 18.4 Million USD | 40.64% |
| 2001 | 13.08 Million USD | 20.04% |
| 2000 | 10.9 Million USD | -1.25% |
| 1999 | 11.04 Million USD | 15.94% |
| 1998 | 9.52 Million USD | 17.56% |
| 1997 | 8.1 Million USD | 65.31% |
| 1996 | 4.9 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 27.17 Million USD | 39.71% |
| 2024 Q2 | 41.5 Million USD | 52.71% |
| 2023 Q2 | 1.49 Million USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 FY | 27.96 Million USD | 0.0% |
| 2023 Q3 | 7.01 Million USD | 368.85% |
| 2023 Q4 | 19.45 Million USD | 177.35% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2021 FY | - USD | -100.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2020 Q2 | 10.09 Million USD | -17.58% |
| 2020 Q1 | 12.24 Million USD | 11.35% |
| 2020 Q3 | 14.22 Million USD | 41.01% |
| 2020 Q4 | - USD | -100.0% |
| 2020 FY | 22.33 Million USD | -62.28% |
| 2019 Q3 | 14.22 Million USD | -18.94% |
| 2019 Q4 | 10.99 Million USD | -22.73% |
| 2019 Q2 | 17.55 Million USD | 6.8% |
| 2019 Q1 | 16.43 Million USD | -21.43% |
| 2019 FY | 59.21 Million USD | -42.66% |
| 2018 Q1 | 33.29 Million USD | -2.79% |
| 2018 FY | 103.26 Million USD | -40.22% |
| 2018 Q2 | 29.23 Million USD | -12.2% |
| 2018 Q3 | 19.82 Million USD | -32.17% |
| 2018 Q4 | 20.92 Million USD | 5.52% |
| 2017 Q2 | 46.31 Million USD | -11.8% |
| 2017 Q1 | 52.5 Million USD | 21.87% |
| 2017 FY | 172.74 Million USD | 14.97% |
| 2017 Q4 | 34.24 Million USD | -13.68% |
| 2017 Q3 | 39.67 Million USD | -14.33% |
| 2016 Q3 | 32.08 Million USD | -17.42% |
| 2016 Q2 | 38.85 Million USD | 7.3% |
| 2016 Q1 | 36.21 Million USD | -16.49% |
| 2016 FY | 150.24 Million USD | -13.26% |
| 2016 Q4 | 43.08 Million USD | 34.28% |
| 2015 Q3 | 47.32 Million USD | -4.97% |
| 2015 Q4 | 43.36 Million USD | -8.35% |
| 2015 Q1 | 32.72 Million USD | 444.12% |
| 2015 Q2 | 49.79 Million USD | 52.16% |
| 2015 FY | 173.2 Million USD | 1072.31% |
| 2014 Q1 | 9.17 Million USD | 48.49% |
| 2014 FY | 14.77 Million USD | -34.17% |
| 2014 Q4 | -9.51 Million USD | -235.32% |
| 2014 Q2 | 8.08 Million USD | -11.91% |
| 2014 Q3 | 7.02 Million USD | -13.04% |
| 2013 Q1 | 5.14 Million USD | -29.69% |
| 2013 FY | 22.44 Million USD | -14.01% |
| 2013 Q3 | 5.58 Million USD | 0.76% |
| 2013 Q2 | 5.54 Million USD | 7.8% |
| 2013 Q4 | 6.17 Million USD | 10.68% |
| 2012 FY | 26.1 Million USD | -19.94% |
| 2012 Q4 | 7.31 Million USD | 35.42% |
| 2012 Q1 | 7.36 Million USD | -14.9% |
| 2012 Q2 | 6.06 Million USD | -17.66% |
| 2012 Q3 | 5.39 Million USD | -10.92% |
| 2011 Q3 | 10.43 Million USD | 54.51% |
| 2011 FY | 32.6 Million USD | -12.12% |
| 2011 Q4 | 8.64 Million USD | -17.11% |
| 2011 Q1 | 6.76 Million USD | -49.71% |
| 2011 Q2 | 6.75 Million USD | -0.16% |
| 2010 Q2 | 7.51 Million USD | -30.78% |
| 2010 FY | 37.09 Million USD | -11.93% |
| 2010 Q4 | 13.45 Million USD | 22.75% |
| 2010 Q1 | 10.85 Million USD | 2.51% |
| 2010 Q3 | 10.95 Million USD | 45.82% |
| 2009 Q3 | 9.89 Million USD | 3.37% |
| 2009 FY | 42.11 Million USD | 9.06% |
| 2009 Q4 | 10.59 Million USD | 7.0% |
| 2009 Q1 | 12.05 Million USD | 27.34% |
| 2009 Q2 | 9.57 Million USD | -20.57% |
| 2008 Q1 | 10.86 Million USD | 2.88% |
| 2008 Q4 | 9.46 Million USD | 3.62% |
| 2008 Q3 | 9.13 Million USD | -0.2% |
| 2008 FY | 38.61 Million USD | 5.36% |
| 2008 Q2 | 9.15 Million USD | -15.76% |
| 2007 Q4 | 10.56 Million USD | 17.1% |
| 2007 Q3 | 9.01 Million USD | 21.08% |
| 2007 Q2 | 7.44 Million USD | -22.61% |
| 2007 Q1 | 9.62 Million USD | 23.68% |
| 2007 FY | 36.65 Million USD | 59.23% |
| 2006 FY | 23.02 Million USD | -2.45% |
| 2006 Q4 | 7.78 Million USD | 43.98% |
| 2006 Q3 | 5.4 Million USD | 14.15% |
| 2006 Q2 | 4.73 Million USD | -7.12% |
| 2006 Q1 | 5.09 Million USD | -18.58% |
| 2005 Q2 | 6.14 Million USD | -24.19% |
| 2005 Q3 | 3.08 Million USD | -49.74% |
| 2005 FY | 23.59 Million USD | -57.41% |
| 2005 Q1 | 8.1 Million USD | -74.72% |
| 2005 Q4 | 6.26 Million USD | 102.75% |
| 2004 Q1 | 14.35 Million USD | 27.37% |
| 2004 Q2 | 8.99 Million USD | -37.36% |
| 2004 Q4 | 32.06 Million USD | 256.65% |
| 2004 Q3 | 8.99 Million USD | 0.0% |
| 2004 FY | 55.41 Million USD | 120.17% |
| 2003 Q2 | 4.99 Million USD | 41.49% |
| 2003 Q1 | 3.53 Million USD | 44.56% |
| 2003 Q4 | 11.26 Million USD | 110.01% |
| 2003 FY | 25.16 Million USD | 36.73% |
| 2003 Q3 | 5.36 Million USD | 7.34% |
| 2002 FY | 18.4 Million USD | 40.64% |
| 2002 Q1 | 4.56 Million USD | 0.0% |
| 2002 Q2 | 4.99 Million USD | 9.6% |
| 2002 Q3 | 6.35 Million USD | 27.17% |
| 2002 Q4 | 2.44 Million USD | -61.55% |
| 2001 Q2 | 2.43 Million USD | -29.84% |
| 2001 Q4 | 4.56 Million USD | 73.75% |
| 2001 FY | 13.08 Million USD | 20.04% |
| 2001 Q3 | 2.62 Million USD | 7.89% |
| 2001 Q1 | 3.46 Million USD | 19.5% |
| 2000 Q4 | 2.9 Million USD | -3.27% |
| 2000 Q2 | 2.84 Million USD | 43.39% |
| 2000 Q1 | 1.98 Million USD | -71.72% |
| 2000 FY | 10.9 Million USD | -1.25% |
| 2000 Q3 | 3 Million USD | 5.56% |
| 1999 FY | 11.04 Million USD | 15.94% |
| 1999 Q4 | 7 Million USD | 315.17% |
| 1999 Q3 | 1.68 Million USD | 61.38% |
| 1999 Q2 | 1.04 Million USD | -19.54% |
| 1999 Q1 | 1.3 Million USD | -55.51% |
| 1998 Q2 | 2.7 Million USD | 22.73% |
| 1998 Q3 | 1.7 Million USD | -37.04% |
| 1998 FY | 9.52 Million USD | 17.56% |
| 1998 Q4 | 2.92 Million USD | 71.88% |
| 1998 Q1 | 2.2 Million USD | -35.29% |
| 1997 Q4 | 3.4 Million USD | 183.33% |
| 1997 FY | 8.1 Million USD | 65.31% |
| 1997 Q1 | 2.1 Million USD | 75.0% |
| 1997 Q2 | 1.3 Million USD | -38.1% |
| 1997 Q3 | 1.2 Million USD | -7.69% |
| 1996 Q2 | 900 Thousand USD | -57.14% |
| 1996 Q1 | 2.1 Million USD | 0.0% |
| 1996 Q3 | 700 Thousand USD | -22.22% |
| 1996 Q4 | 1.2 Million USD | 71.43% |
| 1996 FY | 4.9 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 93.978% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | 69.417% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 95.066% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 94.256% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 44.719% |
| Journey Medical Corporation | 79.18 Million USD | 64.685% |
| Dynavax Technologies Corporation | 232.28 Million USD | 87.962% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 75.963% |
| Bright Green Corporation | 401.49 Thousand USD | -6864.789% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 95.857% |
| Embecta Corp. | 1.12 Billion USD | 97.505% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -16.064% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -16.064% |
| SCYNEXIS, Inc. | 140.14 Million USD | 80.047% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -380.267% |
| Silver Spike Investment Corp. | 11.72 Million USD | -138.549% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -1349.989% |
| Alpha Teknova, Inc. | 36.68 Million USD | 23.773% |
| Safety Shot Inc | 202.67 Thousand USD | -13697.306% |
| Procaps Group, S.A. | 409.92 Million USD | 93.178% |
| Cosmos Health Inc. | 53.37 Million USD | 47.612% |
| Theratechnologies Inc. | 81.76 Million USD | 65.8% |
| Harrow Health, Inc. | 130.19 Million USD | 78.522% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -119.576% |
| Biofrontera Inc. | 34.07 Million USD | 17.927% |
| DURECT Corporation | 8.54 Million USD | -227.129% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 95.397% |
| Cronos Group Inc. | 88.84 Million USD | 68.525% |
| OptiNose, Inc. | 70.98 Million USD | 60.608% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 93.684% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -329.33% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 93.544% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -128.296% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 29.302% |
| Radius Health, Inc. | 2.88 Billion USD | 99.03% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 13.451% |
| ProPhase Labs, Inc. | 44.38 Million USD | 36.998% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 97.252% |
| Procaps Group S.A. | 409.92 Million USD | 93.178% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -2047.696% |
| Viatris Inc. | 15.42 Billion USD | 99.819% |
| Rockwell Medical, Inc. | 83.61 Million USD | 66.556% |
| Aytu BioPharma, Inc. | 81 Million USD | 65.479% |
| SIGA Technologies, Inc. | 139.91 Million USD | 80.015% |
| Tilray Brands, Inc. | 788.94 Million USD | 96.456% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 78.198% |
| Shineco, Inc. | 9.8 Million USD | -185.283% |
| PetIQ, Inc. | 1.1 Billion USD | 97.462% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -232925.0% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 98.518% |
| Alimera Sciences, Inc. | 80.75 Million USD | 65.373% |
| Assertio Holdings, Inc. | 152.06 Million USD | 81.612% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -60.55% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -2497.814% |
| Hempacco Co., Inc. | 4.04 Million USD | -591.189% |
| Talphera, Inc. | 651 Thousand USD | -4195.392% |
| Alvotech | 91.43 Million USD | 69.417% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 91.168% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 97.843% |
| Currenc Group, Inc. | 53.25 Million USD | 47.493% |
| Kamada Ltd. | 144.75 Million USD | 80.683% |
| Indivior PLC | 1.09 Billion USD | 97.442% |
| Evoke Pharma, Inc. | 5.18 Million USD | -439.761% |
| Flora Growth Corp. | 76.07 Million USD | 63.241% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -2497.814% |
| Evolus, Inc. | 202.08 Million USD | 86.163% |
| HUTCHMED (China) Limited | 837.99 Million USD | 96.663% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 95.661% |
| Akanda Corp. | 2.16 Million USD | -1194.552% |